Table 2.
Univariate analysis of the association between patients' characteristics and T790M status of rebiopsy
| Characteristic | No. | T790M status |
p-valuea) | |
|---|---|---|---|---|
| Positive | Negative | |||
| Age (yr) | ||||
| ≤ 60 | 103 | 51 (49.5) | 52 (50.5) | 0.402 |
| > 60 | 102 | 44 (43.1) | 58 (56.9) | |
| Sex | ||||
| Male | 76 | 33 (43.4) | 43 (56.6) | 0.563 |
| Female | 129 | 62 (48.1) | 67 (51.9) | |
| Smoking status | ||||
| Non-smokers | 162 | 79 (48.8) | 83 (51.2) | 0.229 |
| Current/Former-smokers | 43 | 16 (37.2) | 27 (62.8) | |
| Baseline EGFR mutation status | ||||
| 19Del | 111 | 61 (55.0) | 50 (45.0) | 0.022 |
| L858R | 83 | 31 (37.3) | 52 (62.7) | |
| Others | 11 | 3 (27.3) | 8 (72.7) | |
| First-line TKI | ||||
| Gefitinib | 94 | 47 (50.0) | 47 (50.0) | 0.188 |
| Erlotinib | 98 | 45 (45.9) | 53 (54.1) | |
| Afatinib | 13 | 3 (23.1) | 10 (76.9) | |
| Best response of first line TKI | ||||
| Stable disease | 29 | 12 (41.4) | 17 (58.6) | 0.688 |
| Partial response | 176 | 83 (47.2) | 93 (52.8) | |
| PFS of first-line TKI | ||||
| ≤ 11 mo | 107 | 42 (39.3) | 65 (60.7) | 0.036 |
| > 11 mo | 98 | 53 (54.1) | 45 (45.9) | |
| Rebiopsy site | ||||
| Primary | 68 | 23 (33.8) | 45 (66.2) | 0.012 |
| Metastases | 137 | 72 (52.6) | 65 (47.4) | |
Values are presented as number (%). EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PFS, progression-free survival.
a)
By Fisher exact test.